Drug Detail

Information about IPI-493

Generic Name
IND	IPI-493
Brand Name (US)
Manufacturer	Infinity
Drug Type	HSP90 inhibitor
Delivery	Oral
Approval Status	Development discontinued
Indications
Overall Strategy	KIT Protein Based
Strategy	Destroy KIT
Drug Category	HSP90 inhibitor

A phase I study of IPI-493 has been terminated.
According to ClinicalTrials.gov, Drug exposure of retaspimycin HCl (IPI-504) was superior to IPI-493, Infinity will focus exclusively on retaspimycin.